New chemotherapy agents in the treatment of advanced non-small cell lung cancer: An update including data from the seventh world conference on lung cancer
1995; Elsevier BV; Volume: 12; Linguagem: Inglês
10.1016/s0169-5002(10)80007-8
ISSN1872-8332
AutoresRobert L. Comis, David Friedland,
Tópico(s)Lung Cancer Treatments and Mutations
ResumoOver the past two decades, modest gains have been made in chemotherapy for non-small cell lung cancer with the addition of cisplatin-based regimens to the therapeutic armamentarium. Over the last decade, several new agents with significant activity have reached the level of Phase II and III testing. This list of new drugs includes: navelbine, the taxanes--taxol and taxotere, gemcitabine, edatrexate and the camptothecins--irinotecan and topotecan. During this period, oral etoposide and epirubicin were re-investigated and biological agents such as the retinoids, interferons and interleukins were also explored as alternatives to traditional chemotherapy. As these new drug investigations proceeded, basic scientists made important discoveries which are now beginning to be applied to therapy. The future promises to combine these active new drugs with therapies directed against targets unique to non-small cell lung cancer cells.
Referência(s)